Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Induction Therapy with Novel Agents Improves Relapse-Free Survival After Autologous Stem-Cell Transplantation in Multiple Myeloma

Sandra Eder, Wolfgang Lamm, Michaela Gruber, Beatrice Schauer, Jutta Ackermann, Heinz Gisslinger, Johannes Drach

Blood (2011) 118 (21): 4494.

https://doi.org/10.1182/blood.V118.21.4494.4494

Published: 2011

Journal Articles

UDP Glucuronosyltransferase 2B17 Double Deletion Genotype Is An Independent Marker for Poor Prognosis In Multiple Myeloma

Michaela Gruber, Sandra Eder, Trang Le, Jutta Ackermann, Katrina Vanura, Ulrich Jaeger, Johannes Drach

Blood (2010) 116 (21): 2955.

https://doi.org/10.1182/blood.V116.21.2955.2955

Published: 2010

Journal Articles

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.

Viktoria Odelga, MD, Jutta Ackermann, Verena Sagaster, MD, Hannes Kaufmann, MD, Christoph Zielinski, MD, Johannes Drach, MD

Blood (2007) 110 (11): 4845.

https://doi.org/10.1182/blood.V110.11.4845.4845

Published: 2007

Journal Articles

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma.

Johannes Drach, MD, Verena Sagaster, MD, Victoria Odelga, MD, Hannes Kaufmann, MD, Jutta Ackermann, Markus Galhuber, Niklas Zojer, MD, Elisabeth Küenburg, MD, Christoph Zielinski, MD, Rotraud Wieser, MD, Heinz Ludwig, MD

Blood (2006) 108 (11): 3398.

https://doi.org/10.1182/blood.V108.11.3398.3398

Published: 2006

Journal Articles

Short Survival, Despite Promising Response Rates, after Bortezomib Treatment of Multiple Myeloma Patients with a 13q-Deletion.

Johannes Drach, MD, E. Kuenburg, MD, Verena Sagaster, MD, Niklas Zojer, MD, Hannes Kaufmann, MD, Jutta Ackermann, Heinz Ludwig, MD

Blood (2005) 106 (11): 509.

https://doi.org/10.1182/blood.V106.11.509.509

Published: 2005

Journal Articles

The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance.

Johannes Drach, MD, Jutta Ackermann, Catrin Baldia, MD, Hannes Kaufmann, MD, Thomas Noesslinger, MD, Heinz Gisslinger, MD, Sonja Seidl, MD, Verena Sagaster, MD, Andrea Keck, MD, Heinz Ludwig, MD, Ulrich Jaeger, MD, Christoph Zielinski, MD

Blood (2004) 104 (11): 4873.

https://doi.org/10.1182/blood.V104.11.4873.4873

Published: 2004

Journal Articles

Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.

Hannes Kaufmann, MD, Catrin Baldia, MD, Jutta Ackermann, Thomas Noesslinger, MD, Heinz Gisslinger, MD, Ulrich Jaeger, MD, Verena Sagaster, MD, Sonja Seidl, MD, Andrea Keck, MD, Heinz Ludwig, MD, Ingrid Simonitsch-Klupp, MD, Christoph Zielinski, MD, Johannes Drach, MD

Blood (2004) 104 (11): 3459.

https://doi.org/10.1182/blood.V104.11.3459.3459

Published: 2004

Journal Articles

Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization

Niklas Zojer, Robert Königsberg, Jutta Ackermann, Elke Fritz, Susanne Dallinger, Elisabeth Krömer, Hannes Kaufmann, Lucia Riedl, Heinz Gisslinger, Susanne Schreiber, Renate Heinz, Heinz Ludwig, Heinz Huber, Johannes Drach

Blood (2000) 95 (6): 1925–1930.

https://doi.org/10.1182/blood.V95.6.1925

Published: 2000

Journal Articles

Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy

Johannes Drach, Jutta Ackermann, Elke Fritz, Elisabeth Krömer, Rudolf Schuster, Heinz Gisslinger, Maria DeSantis, Niklas Zojer, Michael Fiegl, Sebastian Roka, Judith Schuster, Renate Heinz, Heinz Ludwig, Heinz Huber

Blood (1998) 92 (3): 802–809.

https://doi.org/10.1182/blood.V92.3.802

Published: 1998

NARROW

Induction Therapy with Novel Agents Improves Relapse-Free Survival After Autologous Stem-Cell Transplantation in Multiple Myeloma

UDP Glucuronosyltransferase 2B17 Double Deletion Genotype Is An Independent Marker for Poor Prognosis In Multiple Myeloma

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma.

Short Survival, Despite Promising Response Rates, after Bortezomib Treatment of Multiple Myeloma Patients with a 13q-Deletion.

The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance.

Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.

Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization

Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only